Migliaccio-Walle K - Search Results

1

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.

Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q. Tolley K, et al. J Med Econ. 2010;13(3):559-70. doi: 10.3111/13696998.2010.516203. J Med Econ. 2010. PMID: 20812793 Free article.

2

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.

Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. Bozkaya D, et al. Among authors: migliaccio walle k. J Med Econ. 2017 Mar;20(3):297-302. doi: 10.1080/13696998.2016.1258366. Epub 2016 Nov 21. J Med Econ. 2017. PMID: 27822961 Free article.

3

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.

Jesudian AB, Ahmad M, Bozkaya D, Migliaccio-Walle K. Jesudian AB, et al. Among authors: migliaccio walle k. J Manag Care Spec Pharm. 2020 Jun;26(6):750-757. doi: 10.18553/jmcp.2020.26.6.750. J Manag Care Spec Pharm. 2020. PMID: 32463782 Free PMC article.

4

Economic implications of growth hormone use in patients with short bowel syndrome.

Migliaccio-Walle K, Caro JJ, Möller J. Migliaccio-Walle K, et al. Curr Med Res Opin. 2006 Oct;22(10):2055-63. doi: 10.1185/030079906X132631. Curr Med Res Opin. 2006. PMID: 17022865

5

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Getsios D, Migliaccio-Walle K, Caro JJ. Getsios D, et al. Pharmacoeconomics. 2007;25(12):997-1006. doi: 10.2165/00019053-200725120-00003. Pharmacoeconomics. 2007. PMID: 18047386 Review.

6

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ. Simpson KN, et al. Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3. Pharmacoeconomics. 2013. PMID: 23620210

7

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K. Roy A, et al. Among authors: migliaccio walle k. Am Health Drug Benefits. 2015 Jun;8(4):204-15. Am Health Drug Benefits. 2015. PMID: 26157542 Free PMC article.

8

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Caro J, et al. Drugs Aging. 2004;21(10):677-86. doi: 10.2165/00002512-200421100-00005. Drugs Aging. 2004. PMID: 15287825

9

Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis.

Caro JJ, Ishak KJ, Migliaccio-Walle K. Caro JJ, et al. Value Health. 2004 Sep-Oct;7(5):627-35. doi: 10.1111/j.1524-4733.2004.75013.x. Value Health. 2004. PMID: 15367257 Free article.

10

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group. Migliaccio-Walle K, et al. Clin Ther. 2003 Jun;25(6):1806-25. doi: 10.1016/s0149-2918(03)80171-6. Clin Ther. 2003. PMID: 12860500 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters